Dr. Michael Bennett and Dr. Michael McMann from the Retina Institute of Hawai'i and the McMann Institute, respectively, have successfully implanted an FDA-approved eye telescope at a medical center in Honolulu. The telescope is part of CentraSight, a new patient care program. The program is used to treat patients for end-stage, age-related macular degeneration (AMD), which is the leading cause of blindness in older Americans.
Patients with end-stage AMD have a central blind spot, making it nearly impossible to discern faces, read or watch TV. CentraSight is a surgical option that reduces the impact of the central vision blind spot caused by AMD. The telescope operates by projecting images that are straight ahead (normally obstructed by a blind spot) onto still-functioning portions of the retina.
"After decades of research and development, we finally have technology capable of restoring sight and visual function for patients suffering from chronic macular degeneration," said Dr. Bennett. "This is a very exciting breakthrough both in medical history and for patients who never thought they would see again."
For more information, visit www.CentraSight.com or call (888) 999-4134.